Access to Innovation | View Recent

 Date  Name
April 21, 2008 Underlying chronic conditions significantly increase hospital spending in Canada
December 14, 2007 Treatment of rare disorders: U.S and Europe enact legislation to encourage innovation and access while Canada lags behind.
December 05, 2007 Generic drug savings? Canadian consumers pay significantly more for generic drugs than Americans.
July 05, 2007 Last year, prescription drugs were the smallest component of government health care spending growth in Canada
May 22, 2007 Canada appears to lag behind U.S. in progress in the war on cancer
May 21, 2007 Canada accuse un certain retard par rapport aux États-Unis dans le combat contre le cancer
October 04, 2006 Canada’s National Pharmaceutical Strategy: Improving access to medicines or containing costs by limiting patient/physician treatment choices?
September 11, 2006 Growing numbers of employers use care management strategies to combat chronic disease risk factors and contain health benefit costs
August 22, 2006 The prevalence of chronic conditions is much higher among obese Canadians.
February 27, 2006 Focusing on improving health outcomes instead of decreasing access to testing and treatments will do more to contain health spending growth.
December 11, 2005 Despite misleading claims that drugs accounted for most of Canadian health care spending growth, institutional care continues to drive Canadian health spending
November 10, 2005 Community-based asthma education programs help British Columbia cut asthma hospitalizations in half.
October 25, 2005 The case for pharmacist involvement in patient health management.
August 01, 2005 Canadians with asthma have higher health service utilization
June 12, 2005 Covering Treatments for Rare Disorders will have Little Impact on Drug Plan Costs
April 26, 2005 Obesity may overtake smoking as the leading actual cause of death.
April 05, 2005 In 2004 institutional care drove provincial health spending growth.
March 31, 2005 Despite significant increases in drug utilization, hospitalizations for adverse effects have declined in Canada.
February 15, 2005 PHARMACEUTICAL POLICY CONSULTATION PAPER
February 01, 2005 After first year of operation Common Drug Review rejects 60% of drugs reviewed.
January 18, 2005 Conflicting Trends in 2004 Health Spending May Signal Higher Future Health Spending Growth.
November 08, 2004 Shift in Ontario health service utilization between 1996 and 2001 produces significant savings in avoided hospital costs.
October 11, 2004 Ontario initiative to restrict drug benefits is likely to increase overall health costs by negating the potential to improve health outcomes.
September 26, 2004 Providing access to new medicines can help manage the costs associated with the huge growth in the number of Canadians with chronic conditions.
September 15, 2004 Special Report: First Ministers Meeting, September 13-15: Timely access to care emerges as a national priority.
July 13, 2004 Consumers and patients must have an integral role in health decision making in Canada.
May 24, 2004 R&D in Canada lags behind other major industrialized countries, except Italy
May 03, 2004 Canadians with lower incomes are more likely to have poorer health outcomes.
December 08, 2003 Effective treatments can improve the quality of life for those living with asthma and allergies and can save health resources.
September 28, 2003 Slower drug approval times do not improve patient safety.
September 04, 2003 National health survey reveals that Canadians with arthritis/rheumatism have much higher health service utilization.
July 05, 2003 Recognizing the negative impacts of pricing and reimbursement delays, Europe pursues measures to boost pharmaceutical innovation for the benefit of patients.
June 24, 2003 Canadians patients wait longer than patients in other countries for access to new drugs because of lengthy approval times.
May 10, 2003 Increased spending on prescription drugs can help to contain other health costs.
April 08, 2003 Formulary restrictions on antidepressant medications undermine the effective management of depression and related disorders.
March 09, 2003 Innovation versus Imitation: study concludes that patents are significantly more important in the area of pharmaceuticals than in other industries.
February 23, 2003 Mail-order internet pharmacies in Canada cannot meet the needs of American consumers and may cause shortages for Canadian patients.
February 14, 2003 Incremental advances in pharmaceutical innovation help lower drug costs while improving the quality of care.
February 14, 2003 Incremental advances in pharmaceuticals provide the elderly with more treatment options and improved health outcomes.
January 10, 2003 Policies that support incremental as well as breakthrough innovation are essential to improving clinical and economic outcomes in the treatment of diabetes.
December 08, 2002 Recent study shows that long term disability from arthritis in Canada costs $3.4 billion annually in lost productivity.
November 28, 2002 Romanow Commission Special Report
November 18, 2002 Latest data confirms Institutional care as primary cost driver of provincial health spending.
September 30, 2002 Few new medicines are available to those who depend on provincial drug benefit programs.
September 08, 2002 Managing the growth of chronic conditions will challenge Canadian health care delivery.
August 11, 2002 Advertising of prescription drugs can help improve the health of Canadians and save health resources.
July 23, 2002 Shifting costs from hospitals and other institutions to outpatient services and prescription drugs is good news for Canada's health care system.
June 20, 2002 Prescription drugs account for a small proportion of provincial health spending growth
May 16, 2002 Aggressive Management & Monitoring of Diabetes Improves Health & Saves Health Care Resources.
April 28, 2002 Incremental improvements in ulcer/reflux disease drug therapies save hundreds of millions annually, in avoided hospital costs.
March 20, 2002 Increased spending on prescription drugs can lead to reductions in other health costs.